Siemens, Gamma Medica sign worldwide marketing agreement for X-SPECT
Siemens Medical Solutions and Gamma Medica Inc. announced this week at the SNM meeting in Philadelphia that they have expanded the scope of their 2003 marketing agreement.

Under the terms of the new agreement, Siemens will market and distribute Gamma Medica's X-SPECT molecular imaging product worldwide. Since July 2003, Siemens has held exclusive U.S. marketing rights for the system.

X-SPECT is Gamma Medica's second-generation MicroSPECT pre-clinical imaging system. The dual-modality system combines functional nuclear imaging technique, single photon emission computed tomography (SPECT), with anatomical imaging provided by CT. The system images on a scale 1,000 times smaller than clinical systems and is equipped with dedicated features for the in-vivo imaging of small animals in pre-clinical settings.

Since signing the agreement with Siemens last year, Gamma Medica says that X-SPECT sales have increased dramatically and will continue to with the expansion of the pair's contract.

X-SPECT is installed at a variety of universities, medical centers and biotech and pharmaceutical companies. Most recently, Gamma Medica says it completed installation of the pre-clinical imaging system at Mayo Clinic in Rochester, Minn.